KLIRFIBA Trademark

Trademark Overview

On Monday, October 11, 2021, a trademark application was filed for KLIRFIBA with the United States Patent and Trademark Office. The USPTO has given the KLIRFIBA trademark a serial number of 97068218. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, June 3, 2024. This trademark is owned by Alexion Pharmaceuticals, Inc.. The KLIRFIBA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, protein aggregation-related diseases and disorders, neurodegenerative diseases and disorders
klirfiba

General Information

Serial Number97068218
Word MarkKLIRFIBA
Filing DateMonday, October 11, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, June 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 12, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, protein aggregation-related diseases and disorders, neurodegenerative diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 2, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAlexion Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02210
Party NameAlexion Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02210

Trademark Events

Event DateEvent Description
Thursday, October 14, 2021NEW APPLICATION ENTERED
Tuesday, November 2, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, February 25, 2022ASSIGNED TO EXAMINER
Monday, March 7, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 12, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 12, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 7, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 22, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, November 22, 2022SOU EXTENSION 1 FILED
Tuesday, November 22, 2022SOU EXTENSION 1 GRANTED
Thursday, November 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, May 6, 2023SOU TEAS EXTENSION RECEIVED
Saturday, May 6, 2023SOU EXTENSION 2 FILED
Saturday, May 6, 2023SOU EXTENSION 2 GRANTED
Tuesday, May 9, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 10, 2023SOU TEAS EXTENSION RECEIVED
Friday, November 10, 2023SOU EXTENSION 3 FILED
Friday, November 10, 2023SOU EXTENSION 3 GRANTED
Tuesday, November 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 11, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 11, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 11, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, May 24, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, May 24, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, May 24, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 3, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 3, 2024SOU EXTENSION 4 GRANTED
Monday, June 3, 2024SOU EXTENSION 4 FILED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

klirfiba diseases disorders protein aggregation related neurodegenerative metabolic autoimmune inflammatory preparations